Navigation Links
Arimidex-Herceptin Combo Therapy For Breast Cancer-Clinical Trial Findings

News of interest for post menopausal women with breast cancer positive to hormone receptors and HER2 -addition of both Herceptin (trastuzumab) from Roche// and Arimidex (anastrozole) from AstraZeneca to their treatment improves the length of progression free time by 4.8 months.

A Phase III clinical trial sponsored by Roche showed that Arimidex alone inhibited the progression by just 2.4 months after which the cancer continued to progress.

Hormone sensitive breast cancer is seen in 66% of postmenopausal breast cancer and 25% are HER2 positive. The cancer is therefore a very aggressive form and the chances of relapse are higher.

Roche had already announced in May that the Herceptin-Arimidex combination was proving to be particularly effective. It announced the full findings on Monday in Istanbul at the European Society for Medical Oncology Congress.

Dr. Bella Kaufman, from Israel's Chaim Sheba Medical Centre, who had led the trial, said the findings were extremely positive, as double progression free survival is rare in breast cancer trials.

The trial also showed that overall survival was also prolonged to an average of 28.5 months. However this is not considered statistically significant since patients on Arimidex alone have their survival prolonged to 23.9 months.

Additional data showed that introducing anastrozole instead of Tamoxifen in early hormone sensitive breast cancer among postmenopausal women increased their chances of avoiding disease recurrence.

Source-IANS
'"/>




Page: 1

Related medicine news :

1. Drug Combo Works Better for children with ADHD, Tics
2. Scanning Combo Helps Detect Lung Cancer
3. Relief From Asthma With New Combo Therapy
4. Calcium-Vitamin D Combo For Reduced Fracture Risk
5. Drug Combo Improves Performance Of Multiple Sclerosis Drug
6. Alcohol-illusion: Alcohol and Energy Drinks Combo, Maintains Sobriety?
7. HER-2 Positive Breast Cancer Patients May Benefit With a Combo Drug Strategy
8. The Combo Treatment Is Effective to Treat Type 1 Diabetes in Mice
9. Doomed Duo: Obesity and Type 2 Diabetes Combo, Can Nip Life in the Bud
10. Fuzeon and MK-0518 Combo Holds Promise For HIV
11. Germ - Chemo Combo Fights Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/17/2017)... Metairie, Louisiana (PRWEB) , ... January 17, 2017 ... ... JenCare Senior Medical Center joined the Peoples Health network on Dec. 1, ... Medicare beneficiaries. , “JenCare Senior Medical Center is an exciting addition to our ...
(Date:1/17/2017)... ... January 17, 2017 , ... Wettstein Agencies, a ... and business professionals throughout central Colorado, is joining local nonprofit Aurora Warms The ... Warms The Night organization is committed to breaking the cycle of homelessness and ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... offices in Tyler, has announced the latest beneficiary of their thriving community involvement ... nonprofit organization dedicated to fulfilling the dreams of terminally ill patients. Donations to ...
(Date:1/16/2017)... ... January 17, 2017 , ... To provide ... recognized leader in the fast-casual category, announces a hearty and wholesome Winter Menu. ... Breakfast Sandwich, Turkey Mash-Up Sandwich, Cranberry Crunch & Honey Parfait, Slow Cooked Smoky ...
(Date:1/16/2017)... ... 2017 , ... With the Grand Opening Event planned for February 3, 2017, ... teams and the general public. Built in five months by Centerpoint, the 60,000 square ... basketball or pickleball courts. The space is also suitable for indoor soccer and football ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Jan. 17, 2017 Following an initial ... praised the Food and Drug Administration,s (FDA,s) final ... Drug Products by Pharmacies and Outsourcing Facilities." In ... limitation on pre-packaging -- which would have put ... to long term care (LTC) pharmacies.  ...
(Date:1/17/2017)... , Jan. 17, 2017   Anesthesia ... billing and practice management for the anesthesia and ... marijuana, which remains a "clinical conundrum" (as described ... chronic pain practitioners to think carefully before recommending ... 395-page report by the National Academies of Sciences, ...
(Date:1/17/2017)... -- Interpace Diagnostics Group, Inc., (NASDAQ: IDXG ), ... and pathology services for evaluating risks of cancer, announced ... 13, 2017 from the NASDAQ Listing Qualifications notifying the ... of the NASDAQ Stock Market to maintain a minimum ... The letter noted that for the last 10 days ...
Breaking Medicine Technology: